DM
MYGN icon

Deerfield Management’s Myriad Genetics MYGN Stock Holding History

Deerfield Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-505
Closed -$2.27K – 89
2026
Q1 		$2.27K Hold
505
– – ﹤0.01% 82
2025
Q4 		$3.11K Hold
505
– – ﹤0.01% 150
2025
Q3 		$3.65K Hold
505
– – ﹤0.01% 151
2025
Q2 		$2.68K Buy
+505
New +$2.98K ﹤0.01% 124
2013
Q3 		– Sell
-18,777
Closed -$505K – 126
2013
Q2 		$505K Buy
+18,777
New +$544K 0.02% 106

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deerfield Management's MYGN Position: Q2 2026 in Review

Deerfield Management sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 505 shares — an estimated $2.27K sold.

Deerfield Management first reported a position in MYGN in Q2 2013 and held it in 5 quarters. The position peaked at $505K in Q2 2013. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Deerfield Management reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
  • Deerfield Management sold 505 Myriad Genetics shares in Q2 2026, an estimated $2.27K.
  • Deerfield Management first reported a position in Myriad Genetics in Q2 2013 and held it in 5 quarters.
  • Deerfield Management's Myriad Genetics position peaked at $505K in Q2 2013.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.